The proposed clinical trial is the first human, open-label, single dose study of
self-complementary AAV9 carrying the CLN6 gene delivered one-time intrathecally inserted by
a lumbar puncture into Batten CLN6 Disease subjects. One cohort of patients with Batten CLN6
Disease, with confirmed diagnosis, will undergo gene transfer. A minimum of six patients
will be enrolled into the cohort.